Highlights

  • Neuren Pharmaceuticals (ASX:NEU) earned US$23.3 million of H1 2026 DAYBUE royalties, up 29% YoY.
  • H1 2026 revenue rose 8% to A$42.7 million, while profit after tax fell to A$4.9 million.
  • DAYBUE H1 2026 net sales reached US$226 million, 25% above the prior-year period.
  • The company declared a fully franked interim dividend of AUD 0.15 per share under its new dividend policy.

Neuren Pharmaceuticals Limited (ASX:NEU) develops treatments for neurological disorders associated with genetic abnormalities or brain injury, while earning royalties from the licensed Rett syndrome medicine DAYBUE. Its August 2026 half-year results recorded increased royalty income alongside higher clinical development spending and reduced net profit. The company also introduced an interim dividend program and reported progress with its investigational NNZ-2591 therapy. These developments place commercial royalty receipts, clinical trial execution and regulatory milestones at the centre of its current operating profile.

Company Business

Neuren Pharmaceuticals (ASX:NEU) operates through intellectual property licensing and pharmaceutical research. Acadia Pharmaceuticals holds an exclusive worldwide licence to develop and commercialise trofinetide, sold as DAYBUE in the United States for Rett syndrome. Neuren receives royalties and may receive contractual milestone payments when defined commercial conditions are met. This provides a revenue stream distinct from the company’s own drug development activities.

Its investigational therapy NNZ-2591, also called ercanetide, is being developed for Phelan-McDermid syndrome, Pitt Hopkins syndrome and other neurological conditions. The development pipeline includes programs addressing conditions for which treatment choices are limited. Neuren is incorporated in New Zealand and quoted on the Australian Securities Exchange.

Recent Development

In August 2026, Neuren Pharmaceuticals (ASX:NEU) introduced its first dividend policy, linking planned semi-annual distributions to after-tax royalty income less corporate and administrative expenses. The board declared a fully franked H1 2026 dividend of AUD 0.15 per share, scheduled for payment on 7 October 2026. Its stated policy targets distribution of 70% to 100% of the defined available pool, subject to applicable considerations.

Acadia reported H1 2026 DAYBUE net sales of US$226 million, against approximately US$181 million in H1 2025. Adoption of the DAYBUE STIX powder formulation contributed to sales activity during the period. Acadia increased its 2026 worldwide DAYBUE sales guidance to US$480–510 million, with Neuren indicating corresponding anticipated royalty income of US$53–56 million.

European Commission marketing authorisation for DAYBU was granted in August 2026, with a German commercial launch anticipated in early Q4 2026. A first European commercial sale would satisfy the condition for a potential US$35 million milestone payment under Neuren’s licence agreement. A Japanese trial readout was expected between September and November 2026, although clinical and regulatory outcomes remain uncertain.

Financial Performance and Sector Context

For H1 2026, Neuren Pharmaceuticals (ASX:NEU) reported revenue from ordinary activities of A$42.746 million, compared with A$39.723 million in H1 2025, an increase of 8%. Net profit attributable to shareholders declined 68% to A$4.852 million from A$15.031 million. Basic earnings per share fell to 3.83 Australian cents from 11.88 cents. The earnings decrease occurred despite growth in royalties.

Royalty income totalled US$23.3 million, or A$33.2 million, rising 29% in US dollars and 17% in Australian dollars year on year. Research and development expenditure increased by A$12.5 million to A$27.4 million, reflecting progression of the Koala Phase 3 trial. Corporate and administrative costs were A$3.0 million, while interest income totalled A$5.6 million.

Cash and short-term investments amounted to A$287 million at 30 June 2026. The company expects the Phelan-McDermid syndrome program to cost US$80–90 million in total. In rare-disease pharmaceuticals, regulatory evidence requirements, recruitment of eligible patients and commercial access to approved therapies can materially affect the pace of development and revenue recognition.

Risks to Consider

Neuren Pharmaceuticals (ASX:NEU) is exposed to clinical trial recruitment, safety and efficacy outcomes, and regulatory decisions affecting investigational products. Revenue from DAYBUE depends on sales achieved by its commercial partner and the applicable licensing terms. Geographic expansion may encounter reimbursement, launch and prescribing constraints. Clinical expenditure may rise before additional products generate commercial revenue, while royalties denominated in US dollars introduce exchange-rate sensitivity.

What to Watch Next

Monitoring points include patient enrolment and site activation in the Koala Phase 3 study of NNZ-2591 for Phelan-McDermid syndrome, together with progress in its open-label extension study. The company had reported 15 enrolling trial sites in the US and Canada and eight activated extension sites by August 2026. Neuren was also preparing for an FDA meeting regarding Pitt Hopkins syndrome trial design in late October.

Other developments include confirmation of any German DAYBU commercial launch, the timing of the Japanese trofinetide trial results, and updated DAYBUE sales and royalty figures. Future reporting will indicate how clinical spending, royalty receipts and the dividend policy interact across subsequent periods.

Key Insights

Neuren Pharmaceuticals (ASX:NEU) reported higher H1 2026 revenue and royalty income, but lower profit as research expenditure increased. Its new dividend policy adds a cash distribution mechanism linked to royalty earnings, while a substantial research program continues. The main measurable indicators are DAYBUE sales and related royalties, NNZ-2591 clinical recruitment and results, and regulatory or commercial milestones across additional markets.